Kyverna Therapeutics financials
$6.84+0.29%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$39.6M | -$41.4M | -$39.3M | -$38.7M | -$44.4M | -$47.4M | -$41.0M | -$38.8M | -$33.4M | -$29.4M |
| Net income | -$38.3M | -$39.7M | -$37.8M | -$36.8M | -$42.1M | -$44.6M | -$37.5M | -$34.5M | -$28.8M | -$26.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.63 | $-0.66 | $-0.80 | $-0.85 | $-0.97 | $-1.03 | $-0.87 | $-0.80 | $-0.67 | $-1.12 |
| EBITDA | -$39.1M | -$41.0M | -$38.9M | -$38.3M | -$43.9M | -$46.9M | -$40.5M | -$38.2M | -$32.9M | -$28.9M |
| Operating cash flow | -$40.3M | -$41.6M | -$33.5M | -$43.3M | -$31.9M | -$44.9M | -$37.1M | -$27.5M | -$24.2M | -$25.5M |
| Free cash flow | -$40.6M | -$41.6M | -$33.5M | -$43.3M | -$32.0M | -$44.9M | -$37.6M | -$27.6M | -$25.2M | -$26.1M |
| Diluted shares | 60.9M | 60.4M | 47.2M | 43.4M | 43.2M | 43.2M | 43.3M | 43.2M | 43.1M | 23.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $31.8M | $32.2M | $124.1M | $34.2M | $53.4M | $56.9M |
| Short-term investments | $167.6M | $204.3M | $155.2M | $137.0M | $158.2M | $185.8M |
| Total debt | $25.0M | $25.0M | $25.1M | $198.0K | $318.0K | $580.0K |
| Total assets | $219.8M | $257.0M | $293.8M | $187.2M | $226.5M | $260.7M |
| Total liabilities | $54.3M | $61.4M | $61.5M | $35.2M | $42.1M | $36.6M |
| Shareholders' equity | $165.5M | $195.6M | $232.3M | $151.9M | $184.4M | $224.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology